Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study

Tumori

Volumn 91, Issue 2, 2005, Pages 131-134

  Tartarone, Alfredo ^a   Romano, Gianpiero ^a   Iodice, Giovanni ^a   Capobianco, Alba ^a   Coccaro, Mariarosa ^a   Bochicchio, Annamaria ^a   Di Leo, Pasquale ^a   Ardito, Raffaele ^a   Di Renzo, Nicola ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Cisplatin; Docetaxel; Non small cell lung cancer; Weekly administration

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFORMED CONSENT; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL;

EID: 18944389851     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100205     Document Type: Article

References (23)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin, 53: 5-26, 2003.
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J, 311: 899-909, 1995.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer, N Engl J Med, 10: 92-98, 2002.
4. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tron N, Olivares R, Berille J: A multicenter, randomised, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer, 27: 145-157, 2000.
5. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kin Y, Berille J: Prospective randomised trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18: 2095-2103, 2000.
6. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol, 18: 2354-2362, 2000.
7. Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol, 15: 750-758, 1997.
8. Zalcberg J, Millward M, Bishop JF, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J: Phase II study of docetaxel and cisplatin in advanced non small cell lung cancer. J Ciln Oncol, 16: 1948-1953, 1998.
9. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol, 21: 2354-2362, 2000.
10. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol, 22: 254-261, 2004.
11. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T: Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: a Japanese cooperative study. J Clin Oncol, 14: 1649-1655, 1996.
12. Greco FA: Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol, 26 (Suppl 11): 28-31, 1999.
13. Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 16: 2164-2168, 1998.
14. Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Barton JH, Bradof JE, Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. Cancer, 89: 328-333, 2000.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
16. National Cancer Institute Common Toxicity Criteria, version 2.0. http:/ctep.info.nih.gov
17. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clinical Trials 10: 1-10, 1989.
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457-481, 1958.
19. Satoshi T, Minato K, Watanabe S, Takei Y, Ishihara S, Sato K, Kobayashi G, Toi A, Kaira K, Iwasaki Y, Utugi M, Saito R: A phase I study of cisplatin (CDDP) and weekly docetaxel (DCT) in advanced non-small cell lung cancer (NSCLC). Proc ASCO, 19: 531 A, abst no. 2087, 2000.
20. Koizumi T, Tsunoda T, Fujimoto K, Nomura H, Hirai K, Koyama S, Okada K, Kubo K: Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer. Lung Cancer, 34: 125-131, 2001.
21. Tsunoda T, Koizumi T, Hayasaka M, Hiray K, Koyama S, Takabayashi Y, Fujimoto K, Kubo K: Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol, 54: 173-177, 2004.
22. Ohe Y, Niho S, Kakinuma R, Kubota K, Ohmatsu H, Goto K, Nokihara H, Kunitoh H, Saijo N, Aono H, Watanabe K, Tango M, Yokoyama A, Nishiwaki Y: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small cell lung cancer in elderly patients. Ann Oncol, 15: 45-50, 2004.
23. Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, Saijo N, Hanada K, Ogata H: Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol, 22: 2901-2908, 2004.